Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug

14 hours ago 2

Jonathan Ponciano, The Motley Fool

Fri, March 13, 2026 astatine 9:48 AM CDT 4 min read

Deerfield Management Company disclosed a important acquisition of Celcuity (NASDAQ:CELC) successful its February 17, 2026, SEC filing, adding 980,470 shares successful the 4th quarter. The estimated worth of the commercialized is $80.60 million, based connected mean pricing for the period.

According to a SEC filing dated February 17, 2026, Deerfield Management Company bought an further 980,470 shares of Celcuity during the 4th quarter. The estimated worth of this acquisition is $80.60 million, based connected the quarter’s mean closing price. The fund’s quarter-end presumption successful Celcuity was valued astatine $170.95 million, up $134.72 cardinal from the anterior quarter, a fig that includes some caller purchases and stock terms movement.

Top 5 holdings aft the filing:
- NASDAQ: NUVL: $1.74 cardinal (25.4% of AUM)
- NASDAQ: COGT: $321.24 cardinal (4.7% of AUM)
- NASDAQ: PRAX: $266.25 cardinal (3.9% of AUM)
- NYSE: CNC: $265.34 cardinal (3.9% of AUM)
- NASDAQ: VTRS: $251.57 cardinal (3.7% of AUM)
As of Friday, Celcuity shares were priced astatine $114.37, up 1,040% implicit the past twelvemonth and vastly outperforming the S&P 500’s astir 19% summation successful the aforesaid period.

Metric

Value

Price (as of Friday)	$114.37
Market Capitalization	$5.3 billion
Net Income (TTM)	($162.72 million)

Celcuity develops molecularly targeted therapies for cancer, with a absorption connected its pb cause campaigner Gedatolisib and the CELsignia diagnostic level for bosom and ovarian cancer.
The institution operates a clinical-stage biotechnology model, generating worth done cause development, licensing agreements, and proprietary diagnostic testing.
Primary customers see oncology healthcare providers and biopharmaceutical partners targeting patients with hormone receptor positive, HER2-negative, and precocious oregon metastatic bosom cancer.

Celcuity Inc. is simply a biotechnology institution specializing successful precision oncology, leveraging its CELsignia level and targeted therapeutics pipeline. The company’s strategy centers connected identifying circumstantial cellular drivers of crab to alteration much effective, personalized attraction options. Its competitory vantage lies successful proprietary diagnostic capabilities and exclusive improvement rights to caller therapies specified arsenic Gedatolisib.

Celcuity’s pb asset, gedatolisib, targets the PI3K and mTOR signaling pathway, 1 of the astir important maturation pathways driving galore cancers. Rather than inhibiting a azygous node, the therapy blocks aggregate components of the pathway astatine once, and momentum astir that attack has accelerated.

In January, the FDA accepted Celcuity’s caller cause exertion for gedatolisib successful hormone receptor positive, HER2 antagonistic precocious bosom crab and granted the programme precedence review, mounting a determination day of July 17, 2026. The exertion is backed by results from the Phase 3 VIKTORIA-1 proceedings and was submitted done the agency’s real-time oncology reappraisal program, which is intended to shorten regulatory timelines.

The marketplace has taken notice, with shares skyrocketing much than 1,000% implicit the past year. The institution is acceptable to springiness its upcoming quarterly study adjacent week. As of September 30, the steadfast reported having astir $455 successful currency and short-term investments, capable to money operations done adjacent year.

Read Entire Article